Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.259 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Abstract Introduction Bile acids (BAs) are the end products of cholesterol metabolism produced by human and gut microbiome co‐metabolism. Recent evidence suggests gut microbiota influence pathological features of Alzheimer's disease (AD) including neuroinflammation and amyloid‐β deposition. Method Serum levels of 20 primary and secondary BA metabolites from the AD Neuroimaging Initiative (n = 1562) were measured using targeted metabolomic profiling. We assessed the association of BAs with the “A/T/N” (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF) biomarkers, atrophy (magnetic resonance imaging), and brain glucose metabolism ([ 18 F]FDG PET). Results Of 23 BAs and relevant calculated ratios after quality control procedures, three BA signatures were associated with CSF Aβ 1‐42 (“A”) and three with CSF p‐tau181 (“T”) (corrected P < .05). Furthermore, three, twelve, and fourteen BA signatures were associated with CSF t‐tau, glucose metabolism, and atrophy (“N”), respectively (corrected P < .05). Discussion This is the first study to show serum‐based BA metabolites are associated with “A/T/N” AD biomarkers, providing further support for a role of BA pathways in AD pathophysiology. Prospective clinical observations and validation in model systems are needed to assess causality and specific mechanisms underlying this association.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Alzheimer s & Dementia
- Topic
- Drug Transport and Resistance Mechanisms
- Field
- Medicine
- Canadian institutions
- —
- Funders
- National Institute of Biomedical Imaging and BioengineeringCanadian Institutes of Health ResearchNational Institutes of HealthGenentechU.S. National Library of MedicineNational Institute of Neurological Disorders and StrokeIXICOH. Lundbeck A/SServierEisaiNorthern California Institute for Research and EducationUniversity of Southern CaliforniaPfizerBioClinicaBiogenUniversity of California, San DiegoEli Lilly and CompanyU.S. Department of DefenseMeso Scale DiagnosticsAlzheimer's Disease Neuroimaging InitiativeNational Institute of Mental HealthNovartis Pharmaceuticals CorporationBristol-Myers SquibbNational Institute on AgingAlzheimer's AssociationFoundation for the National Institutes of Health
- Keywords
- Cerebrospinal fluidNeuroimagingAtrophyNeuroinflammationNeurodegenerationAlzheimer's diseaseMedicineDementiaAlzheimer's Disease Neuroimaging InitiativeInternal medicinePathologyDiseaseEndocrinologyPsychiatry
- Has abstract in OpenAlex
- yes